We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · October 19, 2021

U.S. Spending Up for Cancer Drugs Lacking Evidence of Survival Benefit

From 2017 to 2019, Medicare spending on 10 accelerated approval drugs with lack of overall survival benefit increased to $569 million

HealthDay

 

Further Reading